Table 1 Baseline characteristics of the entire cohort.
Less or equal to 33 days (N = 534) | More than 33 days (N = 521) | Total (N = 1055) | p-value | |
|---|---|---|---|---|
Age | 0.029 | |||
Mean | 61.1 | 60 | 60.6 | |
Median | 62.2 | 60.9 | 61.4 | |
Range | 23.9–75.8 | 28.7–76.9 | 23.9–76.9 | |
Race | 0.737 | |||
Black | 8 (1.5%) | 12 (2.3%) | 20 (1.9%) | |
Other | 19 (3.6%) | 22 (4.2%) | 41 (3.9%) | |
Unknown | 8 (1.5%) | 8 (1.5%) | 16 (1.5%) | |
White | 499 (93.4%) | 479 (91.9%) | 978 (92.7%) | |
High-risk FISH | 0.029 | |||
No | 289 (61.0%) | 310 (67.8%) | 599 (64.3%) | |
Yes | 185 (39.0%) | 147 (32.2%) | 332 (35.7%) | |
Mobilization method | 0.205 | |||
G-CSF | 223 (41.8%) | 238 (45.9%) | 461 (43.8%) | |
Plerixafor added | 308 (57.7%) | 280 (54.1%) | 588 (55.9%) | |
Conditioning regimen | 0.002 | |||
Full (Mel 200 mg/m2) | 470 (88.0%) | 423 (81.2%) | 893 (84.6%) | |
Reduced (Mel 140 mg/m2) | 49 (9.2%) | 63 (12.1%) | 112 (10.6%) | |
Other | 15 (2.8%) | 35 (6.7%) | 50 (4.7%) | |
Biochemical response at induction | 0.043 | |||
CR | 96 (18.0%) | 91 (17.5%) | 187 (17.7%) | |
VGPR | 215 (40.3%) | 180 (34.5%) | 395 (37.5%) | |
PR | 200 (37.5%) | 211 (40.5%) | 411 (39.0%) | |
Stable disease | 22 (4.1%) | 39 (7.5%) | 61 (5.8%) |
